tirzepatide and binge eating disorder GLP-1RAs Obesity Associated with Disorders GLP-1 Medications and Eating Disorders:

K23 DK116720-01), in addition to research support by Juvenile Diabetes Research Foundation (JDRF), NIDDK/DiaComp, NIDDK/KPMP, Thrasher Research Fund, International Society of Pediatric and Adolescent Diabetes (ISPAD), Colorado Clinical & Translational Sciences Institute (CCTSI) and Center for Womens Health Research at University of Colorado

The peptide targets white adipose tissue while apparently sparing brown adipose tissue entirely

Retatrutide produces greater weight loss than tirzepatide in separate trials, but no direct head-to-head study exists

The most common adverse events associated with GLP-1 receptor agonists are gastrointestinal symptoms, particularly nausea and vomiting, whereas pancreatitis represents a rare but clinically relevant concern

Decreased energy reserve in an animal model of dilated cardiomyopathy